INR 85.81
(-1.35%)
Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|---|
Operating Cash Flow | 42.59 Million | 14.83 Million | 6.27 Million | 24.86 Million | 44.51 Million | 40.17 Million |
Net Income | 24.4 Million | 34.11 Million | 32.32 Million | 17.16 Million | 37.13 Million | 78.88 Million |
Depreciation & Amortization | 19.47 Million | 11.14 Million | 9.75 Million | 11.15 Million | 16 Million | 22.26 Million |
Deferred income taxes | - | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - | - |
Change in working capital | 80 Thousand | -23.55 Million | -28.84 Million | -2.87 Million | 2.11 Million | -41.39 Million |
Other non-cash items | 37.53 Million | -6.86 Million | -6.96 Million | -577.51 Thousand | -10.74 Million | -19.58 Million |
Investing Cash Flow | -67.8 Million | -51.81 Million | -12.43 Million | -5.48 Million | -13.29 Million | -15.72 Million |
Investments in PPE | -27.38 Million | -20.7 Million | -7.57 Million | -5.95 Million | -8.23 Million | -13.14 Million |
Acquisitions | 174 Thousand | 19 Thousand | - | - | - | - |
Investment purchases | - | -19 Thousand | - | - | -546.28 Thousand | -278.65 Thousand |
Sales/Maturities of investments | - | 110 Thousand | - | - | - | - |
Other Investing Activities | -40.59 Million | -31.21 Million | -4.85 Million | 470.21 Thousand | -4.51 Million | -2.29 Million |
Financing Cash Flow | 28.17 Million | 15.71 Million | -6.14 Million | -5.12 Million | -21.25 Million | -6.91 Million |
Debt repayment | -28.17 Million | -14.01 Million | -5.33 Million | -9.53 Million | -20.27 Million | -14.44 Million |
Dividends payments | - | - | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | - |
Other Financing Activities | -1000.00 | 29.73 Million | -805.91 Thousand | 4.4 Million | -978.35 Thousand | 7.52 Million |
Accounts receivables | 26 Thousand | -84.65 Million | 3.43 Million | -22.75 Million | -5.78 Million | -11.73 Million |
Accounts payables | 24 Thousand | 1.61 Million | -3.19 Million | 5.09 Million | 983 Thousand | -12.55 Million |
Inventory | - | -1.61 Million | 3.19 Million | -5.09 Million | -983 Thousand | -21.16 Million |
Other working capital | 30 Thousand | 61.09 Million | -32.28 Million | 19.87 Million | 7.9 Million | 4.05 Million |
Cash at beginning of period | 195.6 Thousand | 70.48 Million | 82.79 Million | 68.53 Million | 58.56 Million | 41.02 Million |
Cash at end of period | 117.59 Million | 49.22 Million | 70.48 Million | 82.79 Million | 68.53 Million | 58.56 Million |
Capital Expenditure | -27.38 Million | -20.7 Million | -7.57 Million | -5.95 Million | -8.23 Million | -13.14 Million |
Effect of forex changes on cash | - | 300.00 | -27.00 | - | 0.31 | 1000.00 |
Net cash flow / Change in cash | 117.4 Million | -21.26 Million | -12.3 Million | 14.25 Million | 9.96 Million | 17.53 Million |
Free Cash Flow | 15.21 Million | -5.87 Million | -1.3 Million | 18.9 Million | 36.27 Million | 27.02 Million |
Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | 6.62 Million | 9.69 Million | 24.4 Million | 7.48 Million | 950 Thousand | 6.53 Million |
Depreciation & Amortization | - | - | 19.47 Million | 6.77 Million | 3.96 Million | 3.36 Million |
Deferred income taxes | - | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - | - |
Change in working capital | - | - | 80 Thousand | - | - | - |
Other non-cash items | -6.62 Million | -9.69 Million | 37.53 Million | -7.48 Million | -950 Thousand | -6.53 Million |
Investing Cash Flow | - | - | -67.8 Million | - | - | - |
Investments in PPE | - | - | -27.38 Million | - | - | - |
Acquisitions | - | - | 174 Thousand | - | - | - |
Investment purchases | - | - | - | - | - | - |
Sales/Maturities of investments | - | - | - | - | - | - |
Other Investing Activities | - | - | -40.59 Million | - | - | - |
Financing Cash Flow | - | - | 28.17 Million | - | - | - |
Debt repayment | - | - | -28.17 Million | - | - | - |
Dividends payments | - | - | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | - |
Other Financing Activities | - | - | -1000.00 | - | - | - |
Accounts receivables | - | - | 26 Thousand | - | - | - |
Accounts payables | - | - | 24 Thousand | - | - | - |
Inventory | - | - | - | - | - | - |
Other working capital | - | - | 30 Thousand | - | - | - |
Cash at beginning of period | - | - | 195.6 Thousand | 94.4 Million | 86.48 Million | 195.6 Thousand |
Cash at end of period | - | - | 117.59 Million | 107.95 Million | 94.4 Million | 6.93 Million |
Capital Expenditure | - | - | -27.38 Million | - | - | - |
Effect of forex changes on cash | - | - | - | - | - | - |
Net cash flow / Change in cash | - | - | 117.4 Million | 13.55 Million | 7.92 Million | 6.73 Million |
Free Cash Flow | - | - | 15.21 Million | 13.55 Million | 7.92 Million | 6.73 Million |
IG6
ALGWF
EXMT
SEMAC
JAGSNPHARM
6262